NASDAQ: LMAT
Lemaitre Vascular Inc Stock

$82.85-0.08 (-0.1%)
Updated Dec 9, 2025
LMAT Price
$82.85
Fair Value Price
$104.67
Market Cap
$1.88B
52 Week Low
$71.42
52 Week High
$105.55
P/E
34.96x
P/B
4.96x
P/S
8.23x
PEG
5.38x
Dividend Yield
0.97%
Revenue
$240.87M
Earnings
$53.34M
Gross Margin
71%
Operating Margin
30.31%
Profit Margin
22.1%
Debt to Equity
0.58
Operating Cash Flow
$73M
Beta
0.8
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

LMAT Overview

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine LMAT's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical

Industry Rating
B
LMAT
Ranked
#16 of 47

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$5.32A
$20.62A
$9.13A
View Top Medical Stocks

Be the first to know about important LMAT news, forecast changes, insider trades & much more!

LMAT News

Overview

Due Diligence Score

Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LMAT scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

LMAT ($82.85) is undervalued by 20.85% relative to our estimate of its Fair Value price of $104.67 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
LMAT ($82.85) is significantly undervalued by 20.85% relative to our estimate of its Fair Value price of $104.67 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
LMAT ($82.85) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more LMAT due diligence checks available for Premium users.

Valuation

LMAT fair value

Fair Value of LMAT stock based on Discounted Cash Flow (DCF)

Price
$82.85
Fair Value
$104.67
Undervalued by
20.85%
LMAT ($82.85) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LMAT ($82.85) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LMAT ($82.85) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

LMAT price to earnings (PE)

For valuing profitable companies with steady earnings

Company
34.96x
Industry
220.47x
Market
45.87x
LMAT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
LMAT is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

LMAT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
4.96x
Industry
3.69x
LMAT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

LMAT price to earnings growth (PEG)

For valuing profitable companies with growth potential

LMAT is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

LMAT's financial health

Profit margin

Revenue
$61.0M
Net Income
$17.4M
Profit Margin
28.4%
LMAT's Earnings (EBIT) of $73.00M... subscribe to Premium to read more.
Interest Coverage Financials
LMAT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$598.1M
Liabilities
$219.1M
Debt to equity
0.58
LMAT's short-term assets ($452.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LMAT's short-term assets ($452.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LMAT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LMAT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$28.8M
Investing
-$27.4M
Financing
-$3.0M
LMAT's operating cash flow ($73.28M)... subscribe to Premium to read more.
Debt Coverage Financials

LMAT vs Medical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
LMATC$1.88B-0.10%34.96x4.96x
ATRCB$1.97B+2.00%-65.11x4.14x
AZTAB$1.63B+1.57%-29.18x0.94x
XRAYC$2.22B+0.09%-2.53x1.50x
KMTSD$1.27B+0.86%N/A6.91x

Lemaitre Vascular Stock FAQ

What is Lemaitre Vascular's quote symbol?

(NASDAQ: LMAT) Lemaitre Vascular trades on the NASDAQ under the ticker symbol LMAT. Lemaitre Vascular stock quotes can also be displayed as NASDAQ: LMAT.

If you're new to stock investing, here's how to buy Lemaitre Vascular stock.

What is the 52 week high and low for Lemaitre Vascular (NASDAQ: LMAT)?

(NASDAQ: LMAT) Lemaitre Vascular's 52-week high was $105.55, and its 52-week low was $71.42. It is currently -21.51% from its 52-week high and 16% from its 52-week low.

How much is Lemaitre Vascular stock worth today?

(NASDAQ: LMAT) Lemaitre Vascular currently has 22,685,994 outstanding shares. With Lemaitre Vascular stock trading at $82.85 per share, the total value of Lemaitre Vascular stock (market capitalization) is $1.88B.

Lemaitre Vascular stock was originally listed at a price of $6.20 in Oct 19, 2006. If you had invested in Lemaitre Vascular stock at $6.20, your return over the last 19 years would have been 1,236.29%, for an annualized return of 14.62% (not including any dividends or dividend reinvestments).

How much is Lemaitre Vascular's stock price per share?

(NASDAQ: LMAT) Lemaitre Vascular stock price per share is $82.85 today (as of Dec 9, 2025).

What is Lemaitre Vascular's Market Cap?

(NASDAQ: LMAT) Lemaitre Vascular's market cap is $1.88B, as of Dec 10, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Lemaitre Vascular's market cap is calculated by multiplying LMAT's current stock price of $82.85 by LMAT's total outstanding shares of 22,685,994.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.